

(DRAFT/UNAPPROVED)

**VIRGINIA BOARD OF PHARMACY  
MINUTES OF FULL BOARD MEETING**

September 9, 2020  
In-Person/Virtual Meeting

Department of Health Professions  
Perimeter Center  
9960 Mayland Drive  
2nd Floor, Board Room 4  
Henrico, Virginia 23233

**CALL TO ORDER:** An in-person meeting of the Board of Pharmacy was called to order at 9:27 AM. Public access to the meeting was offered on-site and via WebEx.

**PRESIDING:** Kristopher Ratliff, Chairman

**MEMBERS PRESENT:** James L. Jenkins, Jr.  
Glen Bolyard  
Melvin L. Boone, Sr.  
Ryan Logan  
Cheryl H. Nelson  
Patricia Richards-Spruill  
Sarah Melton  
Dale St.Clair  
William Lee

**STAFF PRESENT:** Caroline D. Juran, Executive Director  
David E. Brown, D.C., Director, DHP (left at approx. 11am)  
James Rutkowski, Assistant Attorney General  
Elaine Yeatts, Senior Policy Analyst, DHP  
Annette Kelley, Deputy Executive Director  
Ellen Shinaberry, Deputy Executive Director (arrived at approx. noon)  
Kiara Christian, Executive Assistant

**PHARMACISTS AWARDED  
1-HOUR OF LIVE OR REAL-  
TIME INTERACTIVE  
CONTINUING EDUCATION  
FOR ATTENDING MEETING:** Cynthia Warriner  
Patricia Richards-Spruill  
Natalie Nguyen  
Michael Johnson  
Monet Stanford

**QUORUM** With ten members participating, a quorum was established.

**APPROVAL OF AGENDA:** Mr. Ratliff reported that staff recommended additions to the tentative agenda previously provided.

**MOTION:**

**The agenda was unanimously approved as amended as described below:**

- **Insert Adoption of emergency regulation for reporting pediatric immunizations to the Virginia Immunization Information System. (motion by Nelson, seconded by Jenkins)**

**APPROVAL OF PREVIOUS BOARD MEETING MINUTES**

Ms. Juran offered that the August 17 Workgroup Meeting draft minutes should be amended to include Mr. William Lee's participation as a non-voting member under members present at the meeting.

**MOTION:**

**The Board voted unanimously to adopt the minutes for the August 17, 2020 State Protocol workgroup meeting as amended by inserting that William Lee participated as a non-voting member, and adopted the minutes for the other meetings held between June 16, 2020 and August 18, 2020 as presented. ( motion by Jenkins, seconded by Logan)**

**PUBLIC COMMENTS:**

Mr. Ratliff stated as indicated in the meeting notice on Regulatory Townhall and in the agenda package that comments would be received during this public comment period via WebEx from those persons who submitted an email to Caroline Juran no later than 8am on September 9, 2020 indicating that they wish to offer comment. Mr. Ratliff also noted that the Board would receive comment from those persons who indicated they wished to provide comment in-person via the public sign in sheet. Mr. Ratliff noted that the board would not receive comment regarding the petition for rulemaking for pharmaceutical processors as the comment period closed on August 25, 2020.

Dylan Bishop, CannaBizVA, offer comment representing parties on industrial hemp and those that are looking to expand the pharmaceutical processor market with business opportunities in Richmond, VA. Mr. Bishop shared support of the adoption of emergency regulations governing pharmaceutical processors and expanding access by allowing additional dispensary locations and allowing treatment through temporary residence. He asked that there be some additional consideration of the regulation proposing that pharmaceutical processors only have 5% ownership in the requirement. Mr. Bishop offered comment on the adoption of fast-track regulations for use of industrial hemp extract and urged the board to offer some additional specification and consider allowing hemp that may exceed 0.3% to be transferred to the pharmaceutical processors, in lieu of destruction.

Christina Barrille, Executive Director of the Virginia Pharmacists Association (VPhA), welcomed Dr. Melton and Dr. St.Clair to the board. Ms. Barrille asked that the agenda packets be sent earlier to allow time for VPhA to

provide valuable feedback. She asked that the new board members refer to comment submitted by VPhA included in the agenda packet. Dr. Kelly Goode, also representing VPhA, asked the board to remember that pharmacist can use professional judgment and standards of care, encouraged the board to align the protocols with legislation. She also asked the Board to consider mirroring the Naloxone protocol with the Commissioner's protocol to avoid confusion and to include naltrexone as the "other antagonist" in the protocol, similar to Kentucky. For the Hormonal Contraceptive protocol, Dr. Goode recommended that the board consider the algorithm that could restrict access to care, and review the questionnaire for patient readability. Dr. Goode noted that VPhA hoped the board would consider making the notification of the patient's OB/GYN optional. She requested that the board ask the General Assembly to remove the age restrictions on the fluoride protocol. Lastly, Ms. Goode asked the board to consider including devices into the over-the-counter protocol, and asked the board to review the protocols for typos and consistent language.

Mike Ayotte, representing the National Association of Chain Drug Stores, thanked the board for their work on the development of state protocols. He thanked the board for their insertion of the Hormonal Contraceptive regulation that allows the pharmacy to use an electronic form in the pharmacy for patient intake. He asked that the board consider using "additional epinephrine formulations approved by the FDA for anaphylaxis". Mr. Ayotte also urged the board to ensure that all methods of training are approved and authorized in the emergency contraception protocol, and remove the one-hour ACPE-accredited training requirement.

Jodi Roth, Virginia Association of Chain Drug Stores, offered comment in alignment with VPhA and the National Association of Chain Drug Stores.

Jenn Michelle Pedini, Virginia NORML, thanked the board for their work to bring safe access to medical marijuana to Virginians. She offered comment related in support of the proposed pesticide use allowances from the state of Oregon, and for the board to adopt a reasonable resolution to the current pesticide testing issues so the products can be tested prior to being dispensed to patients.

Lisa Davis, Cardinal Testing Labs, offered that the board should narrow the current pesticide testing requirements as it may create issues in Virginia. She also asked that the board consider that laboratory personnel be included in the criminal liability exemptions. Dr. Davis asked that tamper-evident seals be required in the packaging.

Mark Hickman, representing the Virginia Society of Health-Systems Pharmacists (VSHP), welcomed Dr. Melton and Dr. St.Clair to the board. He asked that any submitted letters or changes to the pharmacy agenda be made

available to the public participating via WebEx as well. He offered VSHP's support of the draft regulations for pharmacy technician educational standards. Mr. Hickman shared VSHP's concerns regarding the labeling of prescriptions and supported comments provided by VPhA on this topic. Mr. Hickman asked that the board consider moving forward with providing guidance on the state protocols after adoption. Lastly, Mr. Hickam offered VSHP's support of the drug disposal workgroup's recommendations.

Lisa Smith, parent of a child with intractable epilepsy, shared her positive experience with visiting one of the pharmaceutical processors. She stated families have been waiting for product for 5 years. She also asked that the board consider the comments provided by Lisa Davis regarding pesticide testing.

Michelle Peace, researcher at VCU, offered that it would be important to add tamper-evident packaging as a requirement for added patient safety. She also added that it would be beneficial to narrow the list of pesticide testing to limit the burden of unnecessary testing and to consider Oregon's list of pesticides. Dr. Peace asked that courier and laboratory employees be listed as exempt from criminal liability.

Katie Hellebush, Executive Director of the Virginia Medical Cannabis Coalition (VMCC), shared that the VMCC appreciated the board's help in providing a process for pharmaceutical processors to provide testing of their products. She asked that the board use the Oregon list as a guide in developing a list of approved pesticides. The VMCC supports an expiration date not more than 6 months, and recommends that the board adopt the Oregon list of pesticides and associated thresholds for product testing purposes. VMCC supports the proposed temperature and humidity changes. VMCC asked that the board consider adopting changes to visitor authorization as set forth in the VMCC petition for rulemaking. She asked that the board consider allowing non-pharmacist to witness green waste destruction.

Joy Strand, Executive Vice-President, GreenLeaf Medical, encouraged the board to consider the comments provided by Lisa Smith, and offered that the board and pharmaceutical processors work together in drafting regulations. She asked that the board consider removing the requirement to have a pharmacist witness the destruction of green waste. She stated green waste destruction can occur 2-3 times daily and will occur under camera surveillance. She is not aware of diversion. She requested amendments to the visitor approval process.

Ashley Allen, representing Dharma Pharmaceuticals, shared that they have products ready to go once testing has been completed. She offered that they are in support of recognizing the Oregon listing of pesticides for processor

use and also support the draft information given on the expiration date of cannabis products. Ms. Allen offered support of the comments provided by Joy Strand, and asked that changes made regarding visitors also be made for the dispensing facilities. She asked that the board consider keeping the language ‘other areas’ in regulation for non-pharmacists to access as identified in the code. She stated pharmacists are not needed in the extraction or production area as no special training is required.

Mark Gignac, Executive Director for the Institute of Advanced Learning and Research, recommended that the board adopt the Oregon list for pesticide testing. He stated the adoption of three broad categories for pesticide testing can create ambiguity as there is no definitive list.

Cynthia Warriner, representing Appalachian College of Pharmacy, thanked the protocol workgroup for its expertise with the development of the statewide protocols which will increase access to care. She then offered personal comments requesting the board to consider a liberal approach when developing the out-of-pocket cost protocol. She offered concern for the proposed regulations allowing pharmaceutical processors to purchase hemp extract from the hemp industry.

Hunter Jamerson, representing Dalitso, provided an overview of his written comment to the board regarding the proposed pharmaceutical processor regulations. He requested that stability testing not be required if expiration date does not exceed 6 months.

**DHP DIRECTOR’S REPORT:**

Dr. Brown extended his congratulations to the board’s two new board members, Dr. Melton and Dr. St.Clair. He also thanked the board for their quick response to recent concerns with pesticide testing requirements.

**LEGISLATIVE/  
REGULATORY/ GUIDANCE**

**Report on Regulatory Action:**

Ms. Yeatts reviewed the chart of regulatory action found on page 46. She pointed out the increase in fees action noting that it will become effective on October 14, 2020. She reviewed the action on page 47 related to the emergency action prohibiting products for vaping inhalation with Vitamin E acetate that became effective August 6, 2020. Lastly, she noted that the exempt pharmaceutical processor regulations conforming to legislation and adopted at the June meeting would become effective September 30, 2020.

Mr. Ratliff asked if there was any update to the prohibition against incentives to transfer action. Ms. Yeatts confirmed that there is no updated information at this time.

**ADOPTION OF**

**EMERGENCY  
REGULATIONS  
REGARDING:**

LIMITED USE LICENSE AND  
PERMIT FOR NON-PROFIT  
FACILITIES

Mr. Rutkowski advised that the term “non-profit” is defined in the Virginia tax Code and that those entities satisfying the definition would be recognized by the Board as a non-profit. There was discussion about whether a guidance document should be created to clarify to licensees that the term “non-profit” was being defined by the tax Code.

**MOTION/ACTION ITEM:**

**The board voted unanimously to adopt the emergency regulations for limited-use license and permit for non-profit facilities as presented, to adopt a Notice of Intended Regulatory Action for replacement regulations, and to direct staff to work with counsel to develop a guidance document clarifying the term “non-profit” is as defined in the tax Code. (motion by Nelson, seconded by Richards-Spruill)**

PHARMACEUTICAL  
PROCESSORS -  
*Cannabis dispensing facilities,  
temporary residency,  
controlled substance  
registrations for laboratories*

There was some discussion regarding the requirement of a criminal background check, and if clarification should be provided in a guidance document. Ms. Kelley confirmed that they 5% ownership requirement was in regulations for the pharmaceutical processors and dispensing facilities. The board had some discussion about 18VAC110-60-200, *Responsibilities of the PIC* regarding whether it would be beneficial to clarify that the dispensing sites must be in the same health service area. The board also discussed if it would be reasonable to allow non-pharmacists to access keys, codes, safes, approved vaults, or any other approved equipment pursuant to 18VAC110-60-240, *Security Requirements*.

**MOTION:**

**The board voted unanimously to amend 18VAC110-60-200 by clarifying that the two dispensing facilities a pharmacist-in-charge may oversee must be located within the same health service area, to adopt the emergency regulations for pharmaceutical processor regulations regarding cannabis dispensing facilities, temporary residency, and controlled substance registration for laboratories as amended, and to adopt a Notice of Intended Regulatory Action for replacement regulations. (motion by Nelson, seconded by Boone)**

STATEWIDE PROTOCOL  
FOR PHARMACIST TO  
INITIATE TREATMENT

Ms. Yeatts provided an overview of the proposed emergency regulations regarding statewide protocols for pharmacists to initiate certain treatment. The board determined it would be appropriate to require notification of a patient’s OB/GYN in addition to the primary care provider as recommended by the protocol workgroup.

**MOTION:**

**The board voted unanimously to adopt the emergency regulations for statewide protocols for pharmacists to initiate certain treatment as presented and to adopt a Notice of Intended Regulatory Action for**

**replacement regulations. (motion by Logan, seconded by Nelson)**

**PHARMACY TECHNICIAN  
EDUCATIONAL  
STANDARDS**

Ms. Yeatts reviewed HB1304 and the proposed emergency regulations. There was discussion regarding duplicative language in 18VAC110-21-135.

**MOTION:**

**The board voted unanimously to amend 18VAC110-21-135(B) by replacing “participating” with “progressing toward completion” and deleting subsection D, to adopt the emergency regulations as amended, and to adopt a Notice of Intended Regulatory Action for replacement regulations. (motion by Jenkins, seconded by Lee)**

**ADOPTION OF FINAL  
REGULATIONS PLACING  
CHEMICALS INTO  
SCHEDULE I**

Ms. Yeatts reviewed the exempt action to recommend the 13 drugs be placed into Schedule I.

**MOTION:**

**The board voted unanimously to adopt the final regulation amending 18VAC110-20-322 as presented which places the following chemicals into Schedule I:**

- **N-phenyl-N-(4-piperidinyl)propanamide (other name: Norfentanyl)**
- **2,N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (other name: Isotonitazene)**
- **(2-ethylaminopropyl)benzofuran (other name: EAPB)**
- **2-(ethylamino)-1-phenylheptan-1-one (other name: N-ethylheptedrone)**
- **4-ethyl-2,5-dimethoxy-N-[(2-hydroxyphenyl)methyl]-benzeneethanamine (other name: 25ENBOH)**
- **4-hydroxy-N-ethyl-N-propyltryptamine (other name: 4-hydroxy-EPT)**
- **N-ethyl-1-(3-hydroxyphenyl)cyclohexylamine**
- **1-cyclopropionyl lysergic acid diethylamide (other name: 1cP-LSD)**
- **1-(4-methoxyphenyl)-N-methylpropan-2-amine**
- **methyl 2-[1-(pent-4-enyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name: MDMA-4en-PINACA)**
- **N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butylindazole-3-carboxamide (other name: ADBBUTINACA)**
- **N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-chloropentyl)indazole-3-carboxamide (other name: 5-chloro-AB-PINACA)**
- **(other names: MMB-FUBICA, AMB-FUBICA)**

**(motion Jenkins, seconded by Richards-Spruill)**

**ADOPTION OF FINAL  
REGULATIONS FOR  
LABELING OF DISPENSED  
PRESCRIPTIONS**

Ms. Yeatts reminded the board of the extension of the comment period due to the cancellation of the March public hearing. There was some discussion by the board on what identifiers should be placed on the label to identify pharmacies involved in the dispensing process.

**MOTION:**

**The board voted 4:6 to adopt the final regulation as presented. (motion by Nelson, seconded by Bolyard; opposed by Logan, Lee, Melton, St.Clair, Jenkins, and Ratliff)**

**The board voted 6:3 to withdraw the regulatory action. (motion by Jenkins, seconded by Melton; opposed by Nelson, Richards-Spruill, Bolyard; Boone abstained)**

**ADOPTION OF EXEMPT  
REGULATION REGARDING  
COLLABORATIVE  
PRACTICE AGREEMENTS**

Ms. Yeatts provided a review of the draft amendments to 18VAC110-40-20.

**MOTION:**

**The board voted unanimously to adopt the exempt regulatory amendments of 18VAC110-40-20 as presented. (motion by Nelson, seconded by Richards-Spruill)**

**ADOPTION OF FAST-TRACK  
REGULATION FOR USE OF  
INDUSTRIAL HEMP BY  
PHARMACEUTICAL  
PROCESSORS**

Ms. Yeatts reviewed the draft language suggested for 18VAC110-60-280, Cultivation and production of cannabidiol oil or THC-A oil on page 166 of the agenda packet. Counsel confirmed that hemp exceeding 0.3% THC cannot legally be acquired by a pharmaceutical processor.

**MOTION:**

**The board voted unanimously to adopt the fast-track regulation amending 18VAC110-60- 280 as presented. (motion by Nelson, seconded by Boone)**

**PETITION FOR RULE-  
MAKING REGARDING  
PHARMACEUTICAL  
PROCESSORS**

Ms. Yeatts reminded the board that the petition came from the Virginia Medical Cannabis Coalition asking for amendments to 8 regulations, and offered the options for board action on this topic.

**MOTION:**

**The board voted unanimously to publish a Notice of Intended Regulatory Action and refer the item to the Regulation Committee for further consideration. (motion by Logan, seconded by Jenkins)**

**REPORTING PEDIATRIC  
IMMUNIZATIONS TO THE  
VIRGINIA  
IMMUNIZATION  
INFORMATION SYSTEM**

Ms. Juran offered that the HHS allowance preempts state law during the COVID-19 public health emergency and therefore, pharmacists may move forward and administer the pediatric immunizations in accordance with the HHS allowance. She added that VDH asked to have these immunizations reported to the Virginia Immunization Information System. A handout of draft emergency regulation 18VAC110-20-271 was provided to the board.

**MOTION:**

**The board voted unanimously to adopt the emergency regulation for 18VAC110-20-271 as presented. (motion by Richards-Spruill, seconded by Boone)**

ADOPTION OF FAQS  
REGARDING USE OF  
PESTICIDES BY  
PHARMACEUTICAL  
PROCESSORS, TESTING  
REQUIREMENTS FOR  
PESTICIDE CHEMICAL  
RESIDUE, AND  
ASSIGNMENT OF  
EXPIRATION DATE FOR  
CANNABIS OIL

Ms. Juran reviewed pages 184-185 in the agenda packet containing the draft FAQs regarding Pesticides and the Assigning of Expiration Dates for Cannabis Oil Products. Additionally, she provided a handout containing alternative language for the pesticide chemical residue testing based on recent feedback. The alternative language adopts the Oregon list for pesticide chemical residue testing requirements. The FAQs would be posted to the board's website.

**MOTION:**

**The board voted unanimously to adopt the FAQs as presented pertaining to under what conditions a pharmaceutical processor may use pesticides, what pesticides the board authorizes to address an infestation that could result in a catastrophic loss, and what criteria the board will use to determine compliance with assigning an expiration date for cannabis oil products and to adopt the alternate language on the handout pertaining to what criteria will be used to determine compliance with pesticide chemical residue testing requirements which adopts the Oregon list. (motion by Logan, seconded by Boone)**

ADOPTION OF STATEWIDE  
PROTOCOLS FOR  
PHARMACIST TO INITIATE  
TREATMENT

Ms. Juran reviewed HB1506 beginning on page 186 in the agenda packet and provided an overview of each draft protocol as recommended by the Protocol Workgroup. The board considered the public comment received in support of all forms of education and not limiting certain educational programs to ACPE-accredited programs. The board offered support of a legislative proposal to authorize fluoride supplements for persons under the age of eighteen. There was discussion on whether devices could be included within the protocol to lower out-of-pocket expenses. Board counsel advised against including "devices" in this protocol as he did not believe the law supported this inclusion. There was a robust discussion regarding whether adoption of a protocol that includes devices may place pharmacists in a vulnerable position wherein third party payers may not cover the claim based on the legal concerns with adopting such a protocol based on the current law. Separate from the legal considerations based on the current law, the board strongly supported an ability for pharmacists to prescribe for ancillary devices to reduce patient cost.

**MOTION:**

**The board voted 4:6 to amend the protocol to lower out-of-pocket expense to include devices. (motion by Lee, seconded by Jenkins; opposed by Boone, Nelson, Richards-Spruill, Logan, St.Clair, Bolyard)**

**MOTION:**

**The board voted unanimously to adopt all statewide protocols as presented and recommended by the Protocol Workgroup. (motion by Nelson, seconded by Richards-Spruill)**

**ADOPTION OF  
RECOMMENDATIONS  
OFFERED BY DRUG  
DISPOSAL WORKGROUP**

The board reviewed the recommendations offered by the Drug Disposal Workgroup.

**MOTION:**

**The board voted unanimously to adopt the drug disposal recommendations as presented and recommended by the Drug Disposal Workgroup. (motion by Boone, seconded by Melton)**

**ADOPTION OF  
AMENDMENTS TO  
BYLAWS-DELEGATION OF  
AUTHORITY REGARDING  
EXCEPTIONS TO  
REQUIREMENT FOR PIC TO  
HAVE 2 YEARS OF  
EXPERIENCE**

Ms. Juran commented that the board considered this matter at a past meeting and voted to amend the Bylaws. However, it was realized after the meeting that the Bylaws cannot be amended unless the amendments are provided in writing to the board which was not the case at the previous meeting. Therefore, she requested that the board reconsider the amendment to the Bylaws based on the written material included in the agenda packet.

**MOTION:**

**The board voted unanimously to amend the Bylaws, Guidance Document 110-12, as presented. (motion by Nelson, seconded by Boone)**

**OLD BUSINESS:**

**INFORMATION FOR  
LICENSURE RENEWAL  
NOTIFICATION  
REGARDING DISPENSING  
OF NALOXONE PER  
REQUEST FROM JOINT  
COMMISSION ON HEALTH  
CARE**

Ms. Juran reminded the board of the letter sent to the board by the Joint Commission on Healthcare which asked that information be included in renewal notices sent to pharmacists that references current laws related to dispensing of Naloxone. The board

**MOTION:**

**The board voted unanimously to adopt the naloxone language as presented for inclusion in the pharmacist licensure renewal notification. (motion by Melton, seconded by Logan)**

**NEW BUSINESS:**

**REQUEST TO DELEGATE  
AUTHORITY TO CHAIRMAN  
IN CONSULTATION WITH  
EXECUTIVE DIRECTOR,  
FOR APPOINTING PERSONS  
TO EVALUATION**

Ms. Juran offered that request for applications for Pharmaceutical Processors will begin in October. Ms. Juran clarified that an ad hoc committee would be assigned to review applications as they are received.

COMMITTEE FOR  
PHARMACEUTICAL  
PROCESSOR REQUEST FOR  
APPLICATION PROCESS

**MOTION:**

**The board voted unanimously to delegate authority to the Chairman, in consultation with the Executive Director, appoint persons to the evaluation committee for the upcoming pharmaceutical processor request for application process. (motion by Lee, seconded by Richards-Spruill)**

ADOPTION OF  
PHARMACIST AND  
PHARMACY TECHNICIAN  
WORKFORCE SURVEY  
REPORTS

The Pharmacist and Pharmacy Technician Workforce Survey were included with the agenda packet as Attachments.

**MOTION:**

**The board voted unanimously to adopt the 2019 Pharmacist and Pharmacy Technician Workforce Survey Reports as presented. (motion by Melton, seconded by Bolyard)**

**TRIBUTE TO JOHN HASTY**

Dr. Ellen Shinaberry offered verbal comments recognizing the recent passing of John W. Hasty and honoring his many contributions in the field of Pharmacy, including serving as a former Director of the Department of Health Professions.

**REPORTS:**

CHAIRMAN'S REPORT

Mr. Ratliff thanked everyone for their patience with the meeting. He also thanked Mr. Ryan Logan for chairing the State Protocol Work Group Meetings, and Ms. Nelson for her attendance in his place at the Drug Disposal Workgroup meeting. Mr. Ratliff also welcomed the new board members, and thanked Mr. Boone for his service to the board in light of his recent decision to resign from the board, effective September 30, 2020, due to personal reasons.

REPORT ON BOARD OF  
HEALTH PROFESSIONS

Mr. Logan offered that the Board of Health Professions met on August 20, 2020 and discussed the board study in the need to regulate neuropathic doctors.

REPORT ON LICENSURE  
REPORT

No presentation was provided. Board members were simply referred to the report on Licensure Program found on page 217 of the agenda packet. No questions were asked of staff.

REPORT ON INSPECTION  
PROGRAM

No presentation was provided. Board members were simply referred to the report on the Inspection Program found on pages 218-228 of the agenda packet. No questions were asked of staff.

REPORT ON  
PHARMACEUTICAL  
PROCESSORS

No presentation was provided. Board members were simply referred to the report found in the agenda packet. No questions were asked of staff.

REPORT ON DISCIPLINARY  
PROGRAM

No presentation was provided. Board members were simply referred to the report found in the agenda packet. No questions were asked of staff.

EXECUTIVE DIRECTORS  
REPORT

Ms. Juran commented that the NABP/AACP Districts 1 & 2 meeting was held virtually on 9/8/2020 and three resolutions were submitted to go forward to the NABP Annual meeting in May. No questions were asked of staff.

CLOSED SESSION:

Upon a motion by Ms. Nelson, and duly seconded by Mr. Bolyard, the panel voted 10-0, to convene a closed meeting pursuant to § 2.2-3711(A)(27) of the Code of Virginia (“Code”), for the purpose of deliberation to reach a decision regarding a consent order involving Meds Vs. Vets. Additionally, it was moved that Caroline Juran, Ellen Shinaberry, Kiara Christian and Jim Rutkowski attend the closed meeting.

RECONVENE:

Having certified that the matters discussed in the preceding closed meeting met the requirements of § 2.2-3712 of the Code, the panel re-convened an open meeting and announced the decision. (motion by Nelson, seconded Richards-Spruill)

DECISION:  
*Meds Vs. Vets*

Upon a motion by Dr. St.Clair, and duly seconded by Ms. Nelson, the panel voted 10-0 to accept the consent order proposed by Ms. Shinaberry regarding Meds Vs. Vets.

CLOSED SESSION:

Upon a motion by Ms. Nelson, and duly seconded by Mr. Logan, the panel voted 10-0, to convene a closed meeting pursuant to § 2.2-3711(A)(27) of the Code of Virginia (“Code”), for the purpose of deliberation to reach a decision regarding the matter involving consents orders for Wells Pharmacy LLC, Tennessee, and Wells Pharmacy LLC, Florida. Additionally, it was moved that Caroline Juran, Ellen Shinaberry, Kiara Christian and Jim Rutkowski attend the closed meeting.

RECONVENE:

Having certified that the matters discussed in the preceding closed meeting met the requirements of § 2.2-3712 of the Code, the panel re-convened an open meeting and announced the decision. (motion by Nelson, seconded Jenkins)

DECISION:  
*Wells Pharmacy, TN*

Upon a motion by Dr. Melton, and duly seconded by Dr. St.Clair, the panel voted 10-0 to accept the consent orders for Wells Pharmacy LLC, Tennessee

*Wells Pharmacy, FL*

and Wells Pharmacy LLC, Florida as proposed by Ms. Shinaberry.

**MEETING ADJOURNED:**

4:35 PM

---

Kristopher Ratliff, Chairman

---

Caroline D. Juran, Executive Director

DATE:

---

DATE:

---